Similarly, silencing the FHC gene increases ROS levels in breast cancer and lung cancer cells, activating the CXCR4/CXCL12 pathway, resulting in the acquisition of an epithelial-mesenchymal transition phenotype and promoting proliferation and migration ability21. This evidence concerns the gene CXCL12 and lung carcinoma.